(NASDAQ: NUVL) Nuvalent's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.56%.
Nuvalent's revenue in 2026 is $0.On average, 20 Wall Street analysts forecast NUVL's revenue for 2026 to be $1,110,150,671, with the lowest NUVL revenue forecast at $12,558,280, and the highest NUVL revenue forecast at $3,607,341,091. On average, 19 Wall Street analysts forecast NUVL's revenue for 2027 to be $14,049,644,249, with the lowest NUVL revenue forecast at $3,883,050,913, and the highest NUVL revenue forecast at $24,764,355,315.
In 2028, NUVL is forecast to generate $43,082,116,548 in revenue, with the lowest revenue forecast at $14,954,525,930 and the highest revenue forecast at $90,409,551,150.